High density cell banking methods

US10188099B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10188099-B2
Application numberUS-201414212607-A
CountryUS
Kind codeB2
Filing dateMar 14, 2014
Priority dateMar 15, 2013
Publication dateJan 29, 2019
Grant dateJan 29, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.

First claim

Opening claim text (preview).

We claim: 1. A non-centrifugal method for producing a high-density frozen mammalian cell bank, the method comprising: a) culturing mammalian cells in a perfusion bioreactor to a first cell density by continuously removing growth medium from a culture and replacing with fresh growth medium, wherein the bioreactor is coupled to a cell retention system comprising an alternating tangential flow filtration system including a filter; b) non-centrifugally concentrating the cells cultured in the perfusion bioreactor coupled to the cell retention system, wherein the cells are concentrated to a second cell density greater than the first cell density by removing the growth medium from the culture using the filter and, thereby reducing the volume of the growth medium to produce a concentrated cell population of about 1×10 8 cells/mL; and c) cryopreserving the concentrated cell population to produce a high-density frozen mammalian cell bank, wherein the high-density frozen mammalian cell bank has a post-thaw viability of at least 90%. 2. The method of claim 1 , wherein the filter has a surface area of at least 0.3 m 2 . 3. The method of claim 1 , wherein the filter has a surface area of about 0.5 to about 1.0 m 2 . 4. The method of claim 1 , wherein the filter has a surface area of about 0.7 to about 0.8 m 2 . 5. The method of claim 1 , wherein the filter has a surface area of about 2.0 to about 3.0 m 2 . 6. The method of claim 1 , wherein the filter has a surface area of about 4 to about 5 m 2 . 7. The method of claim 1 , wherein the filter has a pore size of about 0.2 μm. 8. The method of claim 1 , wherein the cryopreserving comprises adding DMSO to the concentrated cell population at a final concentration of about 5% to about 10%, vol/vol. 9. The method of claim 1 , wherein the cryopreserving comprises freezing at least a portion of the concentrated cell population in a container for storage under cryopreservation conditions. 10. The method of claim 9 , wherein the container is a vial. 11. The method of claim 9 , wherein the container has a volume of at least 2 mL. 12. The method of claim 11 , wherein the container has a volume of about 5 mL. 13. The method of claim 9 , wherein the container is a cryobag. 14. The method of claim 13 , wherein the cryobag has a volume of about 5 to about 150 mL. 15. The method of claim 1 , wherein the high-density frozen mammalian cell bank comprises about 4.5×10 8 viable cells. 16. The method of claim 1 , wherein the high-density frozen mammalian cell bank has a cell density of about 1×10 8 viable cells/mL. 17. The method of claim 1 , wherein the perfusion rate in the perfusion bioreactor is about 0.2 nL/cell/day. 18. The method of claim 1 , wherein the perfusion bioreactor cell culture has a pH of about 7 and a dissolved oxygen concentration of about 40%. 19. The method of claim 1 , wherein the perfusion bioreactor is a flexible bag bioreactor. 20. The method of claim 19 , wherein the flexible bag bioreactor has a volume of 10 L. 21. The method of claim 19 , wherein the flexible bag bioreactor has a volume of at least 20 L. 22. The method of claim 19 , wherein the flexible bag bioreactor further comprises at least one dip tube. 23. The method of claim 1 , wherein the high-density frozen mammalian cell bank has a post-thaw viability of at least 95%. 24. The method of claim 1 , wherein the mammalian cells are selected from the group consisting of: CHO, CHO-DBX11, CHO-DG44, CHO-S, CHO-K1, Vero, BHK, HeLa, COS, MDCK, HEK-293, NIH-3T3, W138, BT483, Hs578T, HTB2, BT20, T47D, NSO, CRL7030, HsS78Bst cells, PER.C6, SP2/0-Ag14, and hybridoma cells. 25. The method of claim 1 , wherein the cells are transfected cells. 26. The method of claim 1 , wherein the pH and DO of the culture in the perfusion bioreactor are controlled by automated methods. 27. The method of claim 26 , wherein the pH and DO of the culture in the perfusion bioreactor are controlled through any one or more of the following: adjustment of the mixture of gases that are introduced to the culture, adjustment of the rock rate of the bioreactor, or adjustment of the rock angle of the bioreactor. 28. The method of claim 1 , wherein the pH and DO of the culture in the perfusion bioreactor are controlled by non-automated methods. 29. The method of claim 28 , wherein the bioreactor is rocked at 15 rpm with a rock angle of 8°. 30. A non-centrifugal method for producing a high-density frozen mammalian cell bank, the method comprising: a) culturing mammalian cells in a perfusion bioreactor to a cell density less than 1×10 8 cells/mL by continuously removing growth medium from a culture and replacing with fresh growth medium, wherein the perfusion bioreactor is coupled to an alternating tangential flow filtration system having a filter, wherein the bioreactor comprises a flexible bag bioreactor, and wherein the-filter has a filter surface area of at least 0.3 m 2 and a filter with a MWCO size of at least 50 kDa; b) non-centrifugally concentrating the cells cultured in the perfusion bioreactor coupled to the cell retention system, wherein the cells are concentrated by removing growth medium from the culture and, reducing the volume of the growth medium using the alternating tangential flow filtration system to produce a concentrated cell population having a density of about 1×10 8 cells/mL; c) cryopreserving the concentrated cell population to produce a high-density frozen mammalian cell bank, wherein the cryopreserving comprises adding DMSO to the concentrated cell population to a final concentration of about 5% to about 10%, vol/vol; and wherein the high-density frozen mammalian cell bank has a cell density of about 10 8 cells/mL; and wherein the high-density frozen mammalian cell bank has a post-thaw viability of at least 90%.

Assignees

Inventors

Classifications

  • flexible (flexible containers for laboratory use B01L3/505) · CPC title

  • Means for packing or storing viable microorganisms (casings for storing cell samples A61B10/0096, preservation of living parts of the human or animal body A01N1/10) · CPC title

  • Perfusion · CPC title

  • Hollow fibers (hollow fiber modules in general B01D63/02) · CPC title

  • of cellular or enzymatic activity or functionality, e.g. cell viability · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10188099B2 cover?
The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.
Who is the assignee on this patent?
Genzyme Corp
What technology area does this patent fall under?
Primary CPC classification A01N1/0284. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).